Similarly, upregulation of TRIM8 expression in NAFLD is closely associated with disease progression, but its mutation status and targeted therapeutic potential in clinical samples remain unclear. This evidence concerns the gene TRIM8 and metabolic dysfunction-associated steatotic liver disease.